Suzman DL - Search Results

1

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.

Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES. Boudadi K, et al. Among authors: suzman dl. Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19. Oncotarget. 2018. PMID: 29983880 Free PMC article.

2

Determining the optimal treatment for metastatic castration-resistant prostate cancer: age should not be a factor.

Suzman DL, Eisenberger MA. Suzman DL, et al. Eur Urol. 2014 May;65(5):884-6. doi: 10.1016/j.eururo.2013.10.002. Epub 2013 Oct 16. Eur Urol. 2014. PMID: 24157242 Free PMC article. No abstract available.

3

High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer.

Suzman DL, Antonarakis ES. Suzman DL, et al. Clin Genitourin Cancer. 2014 Apr;12(2):e51-3. doi: 10.1016/j.clgc.2013.11.015. Epub 2013 Nov 14. Clin Genitourin Cancer. 2014. PMID: 24332506 Free PMC article. No abstract available.

4

Bone-targeting agents in prostate cancer.

Suzman DL, Boikos SA, Carducci MA. Suzman DL, et al. Cancer Metastasis Rev. 2014 Sep;33(2-3):619-28. doi: 10.1007/s10555-013-9480-2. Cancer Metastasis Rev. 2014. PMID: 24398856 Free PMC article. Review.

5

Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?

Suzman D, Eisenberger M. Suzman D, et al. Eur Urol. 2014 Nov;66(5):826-8. doi: 10.1016/j.eururo.2014.03.046. Epub 2014 Apr 13. Eur Urol. 2014. PMID: 24751214 No abstract available.

6

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.

Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES. Suzman DL, et al. Prostate. 2014 Sep;74(13):1278-85. doi: 10.1002/pros.22844. Epub 2014 Jul 22. Prostate. 2014. PMID: 25053178 Free PMC article.

7

Castration-resistant prostate cancer: latest evidence and therapeutic implications.

Suzman DL, Antonarakis ES. Suzman DL, et al. Ther Adv Med Oncol. 2014 Jul;6(4):167-79. doi: 10.1177/1758834014529176. Ther Adv Med Oncol. 2014. PMID: 25057303 Free PMC article. Review.

8

In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis.

Suzman DL, Antonarakis ES. Suzman DL, et al. Oncology (Williston Park). 2014 Oct;28(10):880, 882. Oncology (Williston Park). 2014. PMID: 25323614 Free article. No abstract available.

9

Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.

Suzman DL, Zhou XC, Zahurak ML, Lin J, Antonarakis ES. Suzman DL, et al. Prostate Cancer Prostatic Dis. 2015 Mar;18(1):49-55. doi: 10.1038/pcan.2014.44. Epub 2014 Nov 11. Prostate Cancer Prostatic Dis. 2015. PMID: 25384338 Free PMC article. Clinical Trial.

10

Does degree of androgen suppression matter in hormone-sensitive prostate cancer?

Suzman DL, Antonarakis ES. Suzman DL, et al. J Clin Oncol. 2015 Apr 1;33(10):1098-100. doi: 10.1200/JCO.2014.60.1419. Epub 2015 Mar 2. J Clin Oncol. 2015. PMID: 25732171 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

47 results

Search Page